CONMED Corporation (CNMD)

CONMED's stock experienced volatility in the past six months, reaching 52-week lows in September and October 2025. Despite the stock decline, CONMED reported strong financial results for the second quarter of 2025, surpassing earnings and revenue expectations and raising its full-year 2025 guidance. Other notable events include the declaration of a quarterly cash dividend and the appointment of Kim Kelderman to the Board of Directors. The stock was impacted by broader market sell-offs due to US-China trade tensions and new Chinese export controls. Earlier in February 2025, the company's stock underperformed due to disappointing 2025 guidance, ongoing supply chain issues, and concerns about potential tariff impacts on its manufacturing in Mexico.

Demand for CONMED's products and services can be influenced by seasonal trends within the broader healthcare sector. CONMED's Q1 2025 sales growth was noted to be lower than Q4, reflecting seasonal trends. There can be a typical seasonal experience in the third quarter for inpatient admissions and surgeries. There has also been observed pressure on consumer demand for elective procedures, which can fluctuate.

CONMED Corporation is a global medical technology company specializing in surgical and patient care products, operating in the healthcare sector with two primary segments: Orthopedic Surgery and General Surgery. The Orthopedic Surgery segment includes arthroscopy products, powered surgical instruments, sports medicine solutions, imaging systems, and allograft cartilage and tissue. The General Surgery segment includes electrosurgical products, endomechanical instruments, advanced energy solutions, clinical insufflation systems, smoke evacuation devices, endoscopic technologies, and cardiac monitoring products.

CONMED operates in over 100 countries, serving hospitals, surgical centers, and healthcare providers. It has manufacturing facilities in the United States and Mexico, with international sales and distribution offices. Products are distributed through sales subsidiaries and branches in countries including Australia, Austria, Belgium, Brazil, Canada, China, Denmark, Finland, France, Germany, Italy, Japan, Korea, the Netherlands, Poland, Spain, Sweden, and the United Kingdom.

No specific events directly impacting CONMED Corp.'s brand reputation in the past year were explicitly found in the search results. While the company has faced challenges such as supply chain disruptions and stock price declines, these were primarily discussed in terms of financial performance and operational efficiency rather than a direct impact on brand perception among customers or the public. The mention of supply issues not reflecting particularly well on the company in February 2025 could be an indirect factor.

CONMED Corporation has significant institutional ownership, with 575 institutional owners and shareholders holding a total of 48,239,935 shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Earnest Partners LLC. Institutional ownership accounts for approximately 99.2% to 99.87% of the company, while individual insiders hold a smaller percentage, around 0.58% to 0.759% of the shares.